Semaglutide is an FDA-approved GLP-1 receptor agonist marketed as Ozempic and Rybelsus (diabetes) and Wegovy (weight management and cardiovascular risk reduction). Peptide-vendor "research" semaglutide is not the approved product. This page summarizes trial-demonstrated benefits and does not replace product labelling or a clinician's guidance.
Overview
Semaglutide's proven benefits are substantial average weight loss (about 15% of body weight in its pivotal obesity trial), improved blood-glucose control in type 2 diabetes, and — unusually for a weight-loss drug — reductions in hard outcomes: heart attacks, strokes, and kidney disease events, each demonstrated in its own large randomized trial. It works by mimicking the gut hormone GLP-1: boosting insulin only when glucose is high, slowing stomach emptying, and reducing appetite through receptors in the brain.
Weight loss — the trial numbers
The benchmark is STEP 1, a 68-week randomized trial in 1,961 adults with overweight or obesity and no diabetes. On 2.4 mg weekly semaglutide plus lifestyle intervention, mean weight change was −14.9%, vs −2.4% with placebo (NEJM 2021).
The benefit persists only while treatment continues. In STEP 4, everyone took semaglutide for 20 weeks, then half were switched to placebo: the continuing group lost a further 7.9% while the placebo group regained 6.9% (JAMA 2021). Trials and labels treat semaglutide as chronic therapy, the way blood-pressure medicines are — see what happens when you stop weight-loss peptides.
Glycemic control in type 2 diabetes
Semaglutide was a diabetes drug first. Because it stimulates insulin release only when glucose is elevated and suppresses glucagon, it lowers HbA1c with a low intrinsic risk of hypoglycemia (the exception is combination with insulin or sulfonylureas). The SUSTAIN program established its glycemic efficacy against placebo and active comparators, and SUSTAIN-6 — 3,297 patients with type 2 diabetes at high cardiovascular risk — additionally found fewer major cardiovascular events with semaglutide (hazard ratio 0.74; NEJM 2016). An oral formulation showed cardiovascular safety in PIONEER 6 (NEJM 2019).
Heart, kidney, and liver outcomes
What separates semaglutide from earlier weight-loss drugs is outcome data — trials measuring events, not just risk markers:
- Heart: SELECT randomized 17,604 adults with established cardiovascular disease and overweight or obesity but no diabetes. Semaglutide 2.4 mg cut major adverse cardiovascular events by 20% (hazard ratio 0.80, 6.5% vs 8.0%; NEJM 2023). This result added a cardiovascular indication to the Wegovy label.
- Kidney: FLOW, in 3,533 patients with type 2 diabetes and chronic kidney disease, found a 24% lower risk of major kidney disease events — kidney failure, large eGFR loss, or kidney/cardiovascular death (hazard ratio 0.76; NEJM 2024).
- Liver: in a phase 2 trial in biopsy-confirmed NASH, daily semaglutide resolved steatohepatitis in 59% of patients at the highest dose vs 17% on placebo, though fibrosis stage did not significantly improve (NEJM 2021).
The caveats that come with the benefits
Three qualifiers keep the picture honest. First, averages hide spread — some people lose far more than 15%, some little. Second, the benefit is conditional on continuing: a year after stopping, STEP 1 participants had regained roughly two-thirds of their lost weight (Diabetes, Obesity and Metabolism 2022). Third, every trial above used the approved, quality-controlled product on top of lifestyle intervention — results that can't be assumed for unregulated vials. For how these numbers stack up against the strongest competitor, see semaglutide vs tirzepatide.